Showing 1 - 9 results of 9 for search 'Helen L Leavis', query time: 0.03s
Refine Results
-
1
-
2
-
3
In patients with primary Sjögren’s syndrome innate-like MAIT cells display upregulated IL-7R, IFN-γ, and IL-21 expression and have increased proportions of CCR9 and CXCR5-expressin... by Anneline C. Hinrichs, Anneline C. Hinrichs, Aike A. Kruize, Helen L. Leavis, Joel A. G. van Roon, Joel A. G. van Roon
Published 2022-11-01
Article -
4
-
5
CCL5 Release by CCR9+ CD8 T Cells: A Potential Contributor to Immunopathology of Primary Sjögren’s Syndrome by Anneline C. Hinrichs, Anneline C. Hinrichs, Sofie L. M. Blokland, Sofie L. M. Blokland, Aike A. Kruize, Floris P. J. Lafeber, Helen L. Leavis, Joel A. G. van Roon, Joel A. G. van Roon
Published 2022-06-01
Article -
6
Air pollution from livestock farms and the oropharyngeal microbiome of COPD patients and controls by Warner van Kersen, Alex Bossers, Wouter A.A. de Steenhuijsen Piters, Myrna M.T. de Rooij, Marc Bonten, Ad C. Fluit, Dick Heederik, Fernanda L. Paganelli, Malbert Rogers, Marco Viveen, Debby Bogaert, Helen L. Leavis, Lidwien A.M. Smit
Published 2022-11-01
Article -
7
Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren’s syndrome that show potential to predict and monitor clinical re... by Cornelis P J Bekker, Maarten R Hillen, Sofie L M Blokland, Aike A Kruize, Joel AG van Roon, Timothy RDJ Radstake, Cornelia G van Helden-Meeuwsen, Marjan A Versnel, Helen L Leavis, Safae Hamkour, Ana P Lopes, Eefje HM van der Heijden
Published 2023-08-01
Article -
8
Heterozygous Variants in the DNA-binding Domain of c-Myb May Affect Normal B/T Cell Development by Bas M. Smits, Taila Hartley, Ester Dünnebach, Marije Bartels, Kim M. Boycott, Kirstin D. Kernohan, David A. Dyment, Jacques C. Giltay, Elie Haddad, Olga Jarinova, Joris van Montfrans, Annet van Royen-Kerkhof, Lars T. van der Veken, Moniek de Witte, Stefan Nierkens, Anne Pham-Huy, Helen L. Leavis
Published 2022-10-01
Article -
9
Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program by Leanne P. M. van Leeuwen, Leanne P. M. van Leeuwen, Marloes Grobben, Corine H. GeurtsvanKessel, Pauline M. Ellerbroek, Godelieve J. de Bree, Judith Potjewijd, Abraham Rutgers, Hetty Jolink, Frank L. van de Veerdonk, Marit J. van Gils, Rory D. de Vries, Virgil A. S. H. Dalm, Virgil A. S. H. Dalm, VACOPID Research Group, Eric C.M. van Gorp, Faye de Wilt, Susanne Bogers, Lennert Gommers, Daryl Geers, Marianne W. van der Ent, P. Martin van Hagen, Jelle W. van Haga, Bregtje A. Lemkes, Annelou van der Veen, Rogier W. Sanders, Karlijn van der Straten, Judith A. Burger, Jacqueline van Rijswijk, Khadija Tejjani, Joey H. Bouhuijs, Karina de Leeuw, Annick A.J.M. van de Ven, S.F.J. de Kruijf-Bazen, Pieter van Paassen, Lotte Wieten, Petra H. Verbeek-Menken, Annelies van Wengen, Anke H.W. Bruns, Helen L. Leavis, Stefan Nierkens
Published 2024-04-01
Article